<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 368 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page367.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=368">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 368 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 368</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=368"><img src="../thumb/368.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Immunological / Chelating Agents, Ion Exchange Preparations - 24.2 / 25        2020-04 / 331
       enlarg., orthostat. hypotens., syncope, leukocytos., thrombocyto-  Warnings and special precautions: Monit.pts. for signs of hepat.  depend.on hepat. cytochrome P450 syst.clear., eval.pts aft 2yrs on
       pen., MI, paraesthes.         inj./S&S of decr.periph.bld. counts, sev.hepat.impairm., concom.meds.  treatm.recomm.& long-term treatm made on indiv.bas.
       Warnings and special precautions: Monit. white bld cell counts   assoc. with hepat.inj., discont.in case of depress./other sev. psychiatr.  See also MDR page 507.
       dur.use, exerc.clinic.judgm. when admin Mozobil to pts.with periph.  sympts./serious hypersens.reacts., inj. site necros., compl.& different.
       bld. neutrophil counts &gt; 50 000 cells/µl., monit.platelet counts in all   WBC counts/ platel.counts & bld.chem.incl.liv.funct tests recomm.
       pts.underg.apheres., tumour cell mobilisat. in lymphoma/MM pts.  dur.ther., pts.with myelosuppress.may req. more intens.monitor.of
       poss., poss. system./ vasovag.reacts., eval.pts.report.left upper ab-  compl.blood cell counts with different.& platel.counts, pts.with pre- 25   CHELATING AGENTS,
       dom. pain &/scapul./should.pain for splen. integrity., no formal drug   exist. seiz.disord., pts.with pre-exist.signif.card. dis. incl.CHF/coron.
       interact.stud.conduct., teratogen.in animals, ensure effect.contracept.  artery dis./dysrhythm.to be monitor. for worsen.of condit.partic.dur.   ION EXCHANGE
       in women of childbear.potent dur.treatm., elderly, ren. impairm, weight   treatm. nitiat., assess pts.develop. pulm.arter.hypertens., indicat.
       &gt; 175% of ideal BW not investig., safety & effic.in paeds.not est.  sympts. eg.dyspn./fatig., dose titrat.at initiat. of treatm.poss.amelior.  PREPARATIONS
       PEGASYS, Roche [P/S]          flu-like sympts. which may occur at interferon initiat., prophylact.&
                                     concurr. analgesic &/antipyrets.may prev./amelior. flu-like sympts.,
       Peginterferon alfa-2a         safety & effectiven.in pts &lt;18 yrs/ &gt;65 yrs.not est., pregn & lactat.  DESFERAL, Novartis [P/S]
       Indications: HBeAg posit.& negat.chron. hepatit. B.non-cirrhot.&   See also MDR page 465.  Desferrioxamine mesylate.
       mild.cirrhot.adult pts.with compensat. liv.dis.& evid.of vir.replicat./liv   Indications: Fe overload, ac.iron poison., chron. Al overload, diagn.
       inflamm., in combinat.with ribavirin for chron. hepatit. C non-cirrhot.&   REBIF, (Biopharma div) Merck [P/S] &  of Fe storage dis./Al overload.
       mild.cirrhot.adult pts.with elev. transaminases & compensat.liv.dis.  Inteferon beta-1a  (S4) INJ. H2791. 500 mg/vial
       (S4) INJ, 38/26/0180          Indications: Relapsing remitt.multiple scleros.in ambulat. pts.   719110-009: 5x5 ml, R2 751,78
       704197-001: 180 µg/0,5 ml, sngl.pre-fill.syr., R4 518,59  characteris.by at least 2 recurr. attacks of neurologic.dysfunct. over   Dosage: Chron.Fe overload: Indiv.dos.& mode of admin. to childr.
       Dosage: Exper.physic.supervis. Limit.SC admin.to abdom.& thigh.  preceed.2 yrs.  & adults accord.to Fe burden sever. Ferritin.val.fall.bel.1000 ng/ml
       Chron.hepatit.B&C: Recomm.dos.alone/combin. with oral ribavirin:   (S4)REBIJECT 22 INJ, 34/34/0096. 22 µg/0,5 ml.  incr.risk of Desferal toxic. Admin.low.effect.dos. Mean dly. dos. not
       180 µg once wkly x48 wks. Durat. of combin.ther.& dly.ribavirin dos.  717085-001: 12 x prefil.syr., R6 859,67  to exceed 40 mg/ kg in childr.und.3 yrs.
       indiv. based on pts.viral genotype. See manuf.lit.  (S4) REBIJECT 44 INJ, 35/34/0188. 44 µg/0,5 ml  Childr.& adults:
                         3
       Dos.reduc.recomm.if ANC &lt; 750 cells/ mm  Suspend treatm when   717093-001: 12 x prefil.syr., R7 641,67  Serum Ferritin lev.&lt; 2 000 ng/ml:25 mg/kg/day. Serum Ferritin
       ANC count bel. 500 cells / mm  until ANC count returns to 1 000   (S4) REBIDOSE 22 PEN, 34/34/0096. 22 µg/0,5 ml.  lev.2000-3000 ng/ml:35 mg/kg/day. High.lev.may requir.up to 55 mg/
                     3
           3
       cells/ mm . Re-instit.ther.at 90 µg & monit neutrophil count. Dos.re-  890887-007: 12x prefill.pen., R6 859,67  kg/day. Aveg.dly.dos.is betw.20-60 mg/ kg/ day. Inadvis.to regular.ex-
       duct.to 90 µg recomm.if platel.count &lt; 50 000/ mm . Discont.ther.if   (S4) REBIDOSE 44 PEN, 35/34/0188. 44 µg/0,5 ml  ceed.average dly.dos. of 50 mg/kg/day.
                             3
       platel.count bel. 25 000/mm . 3  898891-004: 12x prefill.pen., R7 641,67  Slow SC admin: by means of an infus.pump over 8-12 hrs.for ambul.
       Contraindications: Mod to sev.hepat.impairm., hypersens.to E.coli-  Dosage: Pre-fill.syr.recomm.for first 4 wks. of init.treatm. as pre-  pts. 5-7x/wk. depend.on severity is regard.as effect.
       deriv.prod./polyethylene glycol, auto-immune.hepatit., safety & effic.  fill. pen not suitab.for dos.init. Admin.3x/wk. on same day of wk.&   See lit.for IV infus.dur.bld.transfus./contin.IV infus or IM admin.instructs.
       not est.in pts. und.18 yrs., pregn., lactat., men with pregn partn., sev.  at same time of day.  Vit.C to be given as an adjunct aft.an init.mnth.of reg.ther at dos.of
       pre-exist.card.dis.incl.unstable/uncontroll. card.dis.in prev.6 mnths.,   Rebiject (pre-fill syr.): Init.22 µg SC 3x/wk. accord.to manufact.  up to 200 mg dly. Childr.und.10 yrs: 50 mg & 100 mg for old.childr.
       auto-immune dis.hist., decompensat liv.cirrhos.  prod.lit. When init.ther.to reduc. adverse effs.admin.4,4 µg (0,1 ml)   Do not admin. Vit.C.to pts.with card.fail.
       Side-effects: Decr.in WBC& ANC within 1  2 wks., decr.platel.  dur.first 2 wks , then 11 µg (0,25 ml) in 3  & 4  week & then 22 µg   Ac.Fe poison: Contin.IV admin.prefer.rate of infus: 15 mg/kg/hr and
                          st
                                                      rd
                                                        th
       count., anaem., thyroid funct. abnorm./worsen.thyroid disords.,   (0,5 ml) from 5  week onwards. Incr.dos.only in case of clear clinic.  should be reduc.as soon as situat. permits, usual.aft.4-6 hrs. Do not
                                           th
       psych.disords. incl. hallucinat./suicide ideat./attempt, depress., pal-  need. Eval.recomm.aft.2 yrs. Dos.of Rebif 44: 44 µg SC 3x/wk.accord.  exceed 80 mg/kg in any 24 hr period.Effectiven.of treatm.depend.on
       pitat., cerebr.haemorrh., hypertens., supraventric. arrhythm., CHF,   to manufact.prod.lit.  adeq.urin.output to ensure Fe complex ferrioxamine excret.
       chest pain, MI, atrial fibrillat., CNS effs.incl.memory impairm./coma,   Rebidose (pre-fill.pen): Adults and adolesc. ≥16yrs: Recomm.  Al overload in pts.with end stage ren.fail: Al eliminat. is incr.by
       periph. neuropathy, hepat.decompensat., sev.ac. hypersens.reacts.,   dos: 44 µg (12 mill.IU) 3x/wk. When init.ther.to reduc.adverse effs.  dialys. Admin.once-wkly.5 mg/ kg as slow IV infus.dur.last 60 mins.
       exacerbat.of auto-immune dis., psorias.& sarcoidos.exacerbat./pro-  admin.8,8 µg 3x/wk. dur.first 2 wks, then 22 µg 3x/wk.in 3  & 4   th  of a dialysis sess.for pts.with post-desferrioxamine test ser.Al lev.
                                                              rd
       vocat., fev., ser.infects., ocul.changes incl.papilloed./retin. haemorrh./-  week & then 44 µg  from 5  week onwards.  up to 300 ng/ml & admin.by slow IV infus.5 hrs. prior to dialys.sess.
                                                th
       detachm., pulm./resp.effs.with fatal interstit.pneumonit., pulm.em-  Rebif 22 µg is also given 3x/wk & is recomm.for pts. who cannot   for post-desferrioxamine test ser.Al lev.above 300 ng/ml. Aft.1st.3-
       bol., epistax., URTI, bronchit., oral candidias.,H.Simplex, skin infect.,   toler.high.dos.in view of treat. special.  mnth.course foll.by 4 wk. wash out period do an infus.test. If 2 suc-
       endocardit., otit.externa, hepat.neoplasms, SLE, sarcoidos., thyroidit.,   Contraindications: Human albumin hypersens., pregn.& lactat.,   cess.infus.tests peform.at 1 mnth.interv.yield levels &lt;50 ng/ml above
       anaphylax., idiopath./ thrombot. thrombocytopen.purpura, rheumat.   sev.depress.&/suicid.ideation, inadeq.control.epilep., seiz.hist.,   baseline discont.recomm.
       arthrit., hypothyroid., hyperthyroid., diabet., diabet. ketoacidos., an-  childr.und.16 yrs.  Pts.on CAPD or CCPD: Give 5 mg/kg once wkly. by the intraperi-
       orex., vertigo, earache, hear.loss, exert.dyspn., cough., GI disturbs.  Side effects: Neutropen., lymphopen., leukopen., thrombocytopen.,   ton.route prior to final exchange of the day. May also be giv.IM/slow
       incl.haemorrh., dry mouth, mouth ulcerat., gingiv.bleed., pancreatit.,   anaem., thrombot.microangiop. incl. thrombot.thrombocytopen.pur-  infus./IV/SC. See manuf.lit.for instructs.for use.
       alopec., skin reacts., incr. sweat., tox. epiderm.necrolys., Stev.-John   pura/haemolyt. uraem. syndr., pancytopen., hypothyroid./ hyper-  Contra-indications: Pregn.& lactat.
       syndr., angioed., erythema multiforme, myalg., arthralg., back-/bone   thyroid., GI disords., anaphylact.reacts., asymptomat. transamin.  Side effects: Loss of vis., scotoma, retin. degenerat., optic.neurit.,
       pain, arthrit., musculo-skelet. pain, musc.cramps /weakn., myosit.,   incr., sev.elev.in transaminas., hepatit.with/-out icterus, hepat.fail.,   cataracts, decr.vis.acuity, blurr.vis., night blindn., vis.field defects,
       impot., rigors, asthen., pain, inj. site react., flu-like illn., malaise, hot   autoimmune hepatit., depress., insomn., suic.att., depersonalisat.,   col.vis. impairm., corn.opacit., hear.disturbs., incr.infect. suscept.in
       flushes, decr. weight, subst.overdos., electrol.disturbs., hypoglycaem.   headache, seiz., trans.neurolog. sympts., retin.vasc.disords., prurit.,   Fe overload pts., mucormycos., enterit. Yersinia, bld.dyscras. incl.
       /-glycaem., elev.trigylcerid.  rash, erythemat. rash, maculo-papul.rash, urticar., Quincke’s oed., ery-  thrombocytopen., red-brown. urine discolourat., anaphylax., an-
       Special precautions: Fatal/life threaten. neuropsych./ autoim-  them.multiforme, Stev.Johns. syndr., hair loss, myalg., arthralg., drug-  gioneurot. oed., headache, neurolog.disturbs., precipit./ exacerbat.
       mun./ischaem.& infect. disords. poss.caus./aggrav.theref.discont.  induc. lupus erythematos., inj.site inflammat./reacts/ pain. necros./  of Al-relat.dialys. encephalopathy, periph.neuropathy, paraesthes.,
       with persist. sev./worsen.signs of above mention. condits., ref.to   abscess./infects/cellulit., influenza-like sympts., fatig., rigors, fev., incr.  deafn. neurosensory, tinnnit., hypotens.if admin. precaut. not follow.,
       ribavirin prod.info., std. haematlogic. & biochemic.lab.test recomm.  sweat., dizzin., anorex., palpitat., arrhythm., anx., vasodil., developm.   asthma, ac.resp.distress syndr., lung infiltrat., GI disturbs., urticar.,
       prior to init. ther.rep.at 2-4 wkly.interv., mnthly pregn.test with combi-  of ser.neutralis.antibod.which may atten. respons.  gen.skin rash, arthral./ myalg., growth retardat. & bone disords, ren.
       nat.ther., withdr.ther.if S&S are persist. sev./worsen., concom.potent.   Warnings and special precautions: Treatm. init. und.supervis.  impairm., loc.reacts., pyrex.
       myelosuppress. agents, eval.TSH & T4 lev.prior to init ther., depress.   of experienc.physic., discont.if prog. multiple scleros.devel., abort.  Warnings and special precautions: Teratogenicity in animals, Fe
       hist., monit.for evid.of depress./psych. disords.& discont.if sympts.  potent., adeq. contracept. in women of child-bear.age, inform those   excret.to be determin. bef./aft.Vit.C admin., rapid IV infus.poss. lead to
       develop, monit.pts. with CV dis.& take ECG prior to init ther., poss   becom.pregn.of potent.hazards to the foetus, depress.& suicid. idea-  hypotens./shock, vis.& audit.disturbs.with high dos.esp.when plasma
       reduc./discont.dos of ribavirin in CV disords.& anaem., determ.cause   tion pts.advis.to report sympts. immed., hist.of seiz.& depress., pre-  ferrit.lev.are low, sev. ren.fail., growth retard.in pts.&lt;3 yrs & those with
       of persist.fev., discont.if ALT incr.signific./worsen. ophthalmolog. con-  exist. card. dis., discont.& treat promptly if thrombot. microangiop.   low ser.ferritin lev.on high dos., ac.resp.distress with excess.high IV
       dits./ imp.pulm.funct./worsen.psorias., auto-immune dis., eye exam.  manifest.as thrombot. thrombocytopen. purp./haemolyt.uraem.syndr.   dos.in ac.Fe intoxicat.& thalassaem.pts., if pt.develops fev.accomp.by
       recomm.prior treatm., diab.mellit., hypertens., safety & effic.not est.in   (HUS) presents, inj.site necros., period.review.of pt. self-admin., skin   pharyngit./ac.enterit./abdom.pain withdr.treatm.& instit.approp.bact.
       liv. transplantat., incr lactic acidos.risk in HIV pt. receiv. HAART, HIV   tests & suit.antibiot.treatm., resum. treatm.once infect.clear., monit.
       co-infect pts with advanc. cirrhosis rec.HAART and ribavirin at incr   break.assoc.with swell./fluid drain. from inj.site, discont.unt.heal.has   bm & longitudin.growth in child., pass.into breastmilk, do not give in
                                     occur.if pt. has multip.les., sngl.les.contin treatm.provid. necros. not
       risk of hepat decompensat.& poss.death, monit Child-Pugh score   dos.high.than recomm., poss.card. funct.impairm.with high Vit.C dos.
       in HCV/HIV, adeq.contracept., ren. impairm., concom.theophylline,   too extens., monit.bld.& platelet counts/ thyroid funct./chem.& liv.  theref.do not exceed Vit.C dos.of 200 mg/day in div.dos., monit. card.
                                     funct.tests recomm., signific.liv.dis., alcoh.abuse, sev.ren.& hepat.
       contin.with monother. if intol.to ribavirin.  fail., discont.if icterus/other clinic.sympts./ liv. dysfunct.appear, sev.  funct.in concom Vit.C ther., audiolog.& ophthalmolog. tests recomm.
       Drug interactions: Inhibit of cytochrome P450 1A2 activ., inapprop.  myelosuppress., concom. drugs with narr.therapeut.index largely   bef.start ther./reg. interv.theraft.& discont.immed.if disturbs.occur,
       to mix with other meds.                                    neurolog. dysfunct.poss.exacerbat.in Al-relat. encephalopathy with
       PLEGRIDY, Litha &                                          high dos., poss.dialys. dement. onset precipit., poss. decr.ser.Ca &
                                                                  aggrav. of hyperparathyroid in Al-overload,
       Peginterferon beta-1a.          When adverse reactions or side   Drug interactions: Poss.impair.consciousn.with prochlorperazine,
       Indications: Treatm.of relaps.forms of multiple scleros. to reduce   imp.card.funct.with vit.C dos. &gt;500 mg/day, heparin inj.sol.incom-
       freq.of clinic.exacerbats.& to delay progress. of disabil.   effects, e.g. fatigue, sedation,   patibil., Gallium 67-imag.results poss.disosrt.because of rapid urin.
       (S4) SOL.FOR INJ, 48/32.16/0426, 0427, 0428  impaired psychomotor function   excret.of Desferal-bound Gallium 67 theref.discont. 48 hrs.prior to
       3000254-001: Starter Pack = (1x63 & 1x94 ug prefill.syr., R6 244,87  scintigraphy advis., saline 0,9% not solv.for dry subst.but can be
       3000259-001: 2x125 ug pre-fill.syr., R6 244,87  and visual disturbances have been   employ.aft.reconst. with H20 for furth.dilut.
       Dosage: Admin.SC, train pt in proper techniq.for self-admin. SC inj.,   reported, patients should be advised
       advise pt.to rotate sites for SC inj.                      EXJADE, Novartis [P/S]
       Recomm.dos: 125 mcg inj.SC every 2wks.  not to engage in any activity which   Deferasirox.
       Treatm.initiat.: Dose 1: 63 mcg, Dose 2: 94 mcg, Dose 3: 125 mcg.   Indications: Chron.Fe overload due to bld. transfus. in adults & paed.
       Contin.with full dos.(125 mcg) every 2 wks.thereaft.  requires alert motor and other skills,   pts.(aged 2 yrs.& over), chron.Fe overload in non-transfus.dependen
       Miss.dos.: Admin as soon as pt.remembers, but do not admin 2   such as driving, operating machinery   thalassem.syndr.in pts.10 yrs & old. Ther should be init.when there
       doses within 7 days of each other.                         is evid.of Fe overload (liv.iron concentrat.(LIC) ≥ 5 mg Fe/g dry weight
       Contraindications: Hist.of hypersens.to natur./ recombin.inter-  or climbing dangerous heights until   (dw) or ser.ferritin consist.&gt;800 microgram/L.
       feron beta/peginterferon,        they know how the medication   (S4) DISPERS.TABS, A40/27/0266, 0267, 0268
       Side effects: Headache, GI disords., myalg., arthralg., inj.site   708144-001: 125 mg, 28, R3 171,39
       erythema/ pain/prurit./oed/ warmth/ haematoma/rash, influenza- affects them, or are instructed by their   708147-001: 250 mg, 28, R6 969,67
       like illn., pyrex., chills, asthen., hypertherm., pain, incr.body temp./  treating clinician not to do so.  708148-001: 500 mg, 28, R13 937,52
       alanine aminotransfer./aspartate aminotransfer./ gamma-gluta-  Dosage: Take on an empty stomach 30 mins.bef. food.pref.at same
       myltransfer., prurit.                                      time each day dispers.in 100-200 ml water/apple or orange juice.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page367.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page363.html">363</a>&nbsp;&nbsp;&nbsp;<a href="page364.html">364</a>&nbsp;&nbsp;&nbsp;<a href="page365.html">365</a>&nbsp;&nbsp;&nbsp;<a href="page366.html">366</a>&nbsp;&nbsp;&nbsp;<a href="page367.html">367</a>&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>
             </td>
             <td width="35%"><a href="page369.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page369.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
